Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Executive Summary

• Profound Medical projects Q3 2025 revenue of $5.2‑$5.3 million, an 84%–87% increase versus $2.8 million in the same quarter last year.
• Gross margin is expected to be ~72%, up from 64% a year earlier.
• The company will release full, audited Q3 results on November 13, 2025 and host a conference call at 4:30 p.m. ET.

Key Details

• Preliminary unaudited revenue range for the quarter ended September 30, 2025: $5.2M – $5.3M.
• Year‑over‑year revenue growth: 84%–87%.
• Expected gross margin for Q3 2025: ~72%, compared with 64% in Q3 2024.
• TULSA‑PRO® installed base increased to 67 systems (up from 60), with a target of ≥75 systems by year‑end.
• Full third‑quarter financial results will be announced after market close on Thursday, November 13, 2025.
• Conference call details:
• Date: Nov 13, 2025
• Time: 4:30 p.m. ET
• Registration link: https://register-conf.media-server.com/register/BI1d4819ae421e47ff95ddb48cba2afcea
• Call will be streamed live and archived on Profound’s website under “News & Events” → Investors.

Notable Quotes

• Arun Menawat, CEO & Chairman: “During the third quarter, we achieved new highs in terms of both TULSA‑PRO® installed base growth and existing system utilization, driving record total revenues… our TULSA‑PRO installed base now sits at 67 – up from 60 – and, due to our strong and growing capital sales pipeline, we continue to expect to reach at least 75 by the end of the year.”